STMN1在NSCLC中的表达及其与预后及放疗疗效的相关性研究

Abstract
Figure/Table
References
Related Citation (5)

Download: PDF (7140 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate whether the expression of STMN1 is related to the prognosis of non-small cell lung cancer (NSCLC) and the effect of radiotherapy. Methods Immunohistochemical staining (IHC) was used to detect the expression of STMN1 in NSCLC and normal tissues. The correlation between STMN1 expression level and clinicopathological characteristics of patients was analyzed, and the correlation between STMN1 expression level and progression-free survival (PFS) was studied. STMN1 was identified as an independent prognostic factor for radiotherapy resistance in stage III-IV NSCLC by univariate and multivariate regression analysis. Constructing STMN1 overexpressing plasmids and interfering cell models of A549 and H1299 cells by a lentivirus infection method, verifying the expression of STMN1 and p-STMN1 by a protein immunoblot technology (Western-blot, WB), The effect of STMN1 on radiosensitivity of NSCLC cells was investigated by flow cytotoxicity analysis. The effect of STMN1 on cell invasion and migration was investigated by transwel1 invasion and migration assay. Results The expression level of STMN1 in NSCLC was significantly higher than that in normal lung. The expression level of STMN1 was significantly correlated with tumor differentiation and TNM staging in NSCLC patients, but not with age, sex and histopathological classification. The median PFS in STMN1 overexpression NSCLC was significantly lower than that in STMN1 underexpression. The local control rate of STMN1 overexpression NSCLC after 2 months of radiotherapy was significantly lower than that of STMN1 underexpression. Overexpression of STMN1 inhibited X-ray induced apoptosis of lung cancer cells. After STMN1 overexpression, the invasion and migration of A549 and H1299 cells were significantly enhanced. Conclusion The high expression of STMN is closely related to the low differentiation and TNM staging of tumor. Therefore, STMN1 can be used as an indicator of poor prognosis and resistance to radiotherapy in patients with NSCLC.

Key words： STMN1 non-small cell lung cancer radiotherapy resistence poor prognosis

Received: 30 March 2023

PACS:

R734.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	OUYANG yunjie
	LIU Limin
	CHEN Nishichun
	YIN Xia

Cite this article:

OUYANG yunjie,LIU Limin,CHEN Nishichun等. Preliminary study on STMN1 participating in radiotherapy resistance of NSCLC through apoptosis[J]. HuNan ShiFan DaXue XueBao(YiXueBan), 2024, 21(3): 42-50.

URL:

http://yxb.hunnu.edu.cn/EN/ OR http://yxb.hunnu.edu.cn/EN/Y2024/V21/I3/42

[1] SUNG H, FERLAY J, SIEGEL RL, et al.Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71: 209-249.
[2] SIEGEL RL, MILLER KD, FUCHS HE, et al.Cancer Statistics[J]. CA Cancer J Clin, 2021, 71(1) : 7-33.
[3] SIEGEL RL, MILLER KD, JEMAL A.Cancer statistics[J]. CA Cancer J Clin, 2020, 70(1) : 7-30.
[4] SIEGEL RL, MILLER KD, FUCHS HE, et al.Cancer statistics[J]. CA Cancer J Clin, 2022, 72(1) : 7-33.
[5] ZHANG M, QUAN H, FU L, et al.Third-generation EGFR inhibitor HS-10296 in combination with famitinib, a multi-targeted tyrosine kinase inhibitor, exerts synergistic antitumor effects through enhanced inhibition of downstream signaling in EGFR-mutant non-small cell lung cancer cells[J]. Thorac Cancer, 2021, 12(8) : 1210-1218.
[6] JAFARI NIVLOUEI S, SOLTANI M, et al.A multiscale cell-based model of tumor growth for chemotherapy assessment and tumor-targeted therapy through a 3D computational approach[J]. Cell Prolif, 2022, 55(3): e13187.
[7] ALEXANDER M, KIM SY, CHENG H.Update 2020: Management of Non-Small Cell Lung Cancer[J]. Lung, 2020, 198(6) : 897-907.
[8] CAI Y, FU Y, LIU C, et al.Stathmin 1 is a biomarker for diagnosis of microvascular invasion to predict prognosis of early hepatocellular carcinoma[J]. Cell Death Dis, 2022, 13(2) : 176.
[9] XUN G, HU W, LI B.PTEN loss promotes oncogenic function of STMN1 via PI3K/AKT pathway in lung cancer[J]. Sci Rep, 2021, 11(1): 14318.
[10] ZHANG J, FU J, PAN Y, et al.Silencing of miR-1247 by DNA methylation promoted non-small-cell lung cancer cell invasion and migration by effects of STMN1[J]. Onco Targets Ther, 2016, 9: 7297-7307.
[11] EISENHAUER EA, THERASSE P, BOGAERTS J, et al.New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer. 2009, 45(2) : 228-47.
[12] ALLRED DC, HARVEY JM, BERARDO M, et al.Prognostic and predictive factors in breast cancer by immunohistochemical analysis[J]. Mod Pathol, 1998, 11(2) : 155-68.
[13] BAI T, YOKOBORI T, ALTAN B, et al.High STMN1 level is associated with chemo-resistance and poor prognosis in gastric cancer patients[J]. Br J Cancer, 2017, 116(9) : 1177-1185.
[14] SGUBIN M, PEGORARO S, PELLARIN I, et al.HMGA1 positively regulates the microtubule-destabilizing protein stathmin promoting motility in TNBC cells and decreasing tumour sensitivity to paclitaxel[J]. Cell Death Dis, 2022, 13(5) : 429.
[15] LIOU S, NILFOROUSHAN N, KANG Y, et al.p16 is superior to Stathmin-1 and HSP27 in identifying cervical dysplasia[J]. Diagn Pathol, 2021, 16(1) : 85.
[16] SEOL MY, CHOI SH, YOON HI.Combining radiation with PI3K isoform-selective inhibitor administration increases radiosensitivity and suppresses tumor growth in non-small cell lung cancer[J]. J Radiat Res, 2022, 63(4) : 591-601.
[17] LIU Y, LI L, WU X, et al.MSC-AS1 induced cell growth and inflammatory mediators secretion through sponging miR-142-5p/DDX5 in gastric carcinoma[J]. Aging (Albany NY) , 2021, 13(7) : 10387-10395.
[18] OGUSHI K, YOKOBORI T, NOBUSAWA S, et al.High Tumoral STMN1 Expression Is Associated with Malignant Potential and Poor Prognosis in Patients with Neuroblastoma[J]. Cancers (Basel) , 2023, 15(18) : 4482.
[19] ZENG L, LYU X, YUAN J, et al.STMN1 Promotes Tumor Metastasis in Non-small Cell Lung Cancer Through Microtubule-dependent And Nonmicrotubule-dependent Pathways[J]. Int J Biol Sci, 2024, 20(4) : 1509-1527.
[20] MACHADO-NETO JA, RODRIGUES ALVESl APN, FERNANDES JC, et al.Paclitaxel induces Stathmin 1 phosphorylation, microtubule stability and apoptosis in acute lymphoblastic leukemia cells[J]. Heliyon, 2017, 3(9) : e00405.